ArticleMolecular cancer therapeutics2021

Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.

Samuel J Klempner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.